Black Diamond Financial LLC Acquires 19,000 Shares of CEL-SCI Co. (NYSE:CVM)

Black Diamond Financial LLC lifted its holdings in CEL-SCI Co. (NYSE:CVM) by 35.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,000 shares of the company’s stock after buying an additional 19,000 shares during the period. Black Diamond Financial LLC owned about 0.13% of CEL-SCI worth $84,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Tidal Investments LLC purchased a new stake in shares of CEL-SCI during the 1st quarter valued at $27,000. Chilton Capital Management LLC boosted its holdings in CEL-SCI by 297.4% in the first quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock worth $31,000 after acquiring an additional 12,200 shares in the last quarter. Forthright Family Wealth Advisory LLC purchased a new stake in shares of CEL-SCI during the fourth quarter worth about $45,000. Cutter & CO Brokerage Inc. increased its holdings in shares of CEL-SCI by 29.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock valued at $126,000 after acquiring an additional 24,634 shares in the last quarter. Finally, Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after purchasing an additional 80,001 shares in the last quarter. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

CEL-SCI Trading Up 6.7 %

Shares of CEL-SCI stock opened at $1.28 on Monday. The firm’s 50 day simple moving average is $1.19 and its two-hundred day simple moving average is $1.42. The firm has a market capitalization of $69.32 million, a price-to-earnings ratio of -2.03 and a beta of 0.66. CEL-SCI Co. has a 12-month low of $1.02 and a 12-month high of $3.23. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Analysts predict that CEL-SCI Co. will post -0.52 EPS for the current year.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.